Find a Clinical Trial

Showing 1 - 10 out of 15

Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus

2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of BIIB059 in Participants with Active Subacute
Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus
Erythematosus with or without Systemic Manifestations and Refractory
and/or Intolerant to Antimalarial Therapy (AMETHYST)

Cutaneous disorders

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

PATH-2: PLS240

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE
TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS
WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-2) WITH AN
OPEN-LABEL EXTENSION

Hemodialysis access, Thyroid diseases

All genders

18-80

Recruiting now

Division of Nephrology

Tufts Medical Center

Learn more

MLS-101-206

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

Chronic kidney disease

All genders

18-100

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

I CAN

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A
Nephropathy (IgAN)

IgA

All genders

18+

Recruiting now

Division of Nephrology

Tufts Medical Center

Learn more

Atopic Dermatitis (Eczema)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Atopic dermatitis

All genders

12-17

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

R3R

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Chronic kidney disease

All genders

12+

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

Assist

A Randomized, Double-blind, Placebo-controlled, Crossover Study
of Atrasentan in Subjects with IgA Nephropathy on Sodiumglucose Cotransporter-2 Inhibitors (SGLT2i)

Chronic kidney disease

All genders

18+

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

VX19-NEN-801

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

Chronic kidney disease, Glomerular disease, Kidney diseases, Proteinuria

All genders

12-65

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

AMPLITUDE

A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease

Chronic kidney disease, Nephropathy, Proteinuria

All genders

18-65

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE
TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS
WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-2) WITH AN
OPEN-LABEL EXTENSION

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A
Nephropathy (IgAN)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

A Randomized, Double-blind, Placebo-controlled, Crossover Study
of Atrasentan in Subjects with IgA Nephropathy on Sodiumglucose Cotransporter-2 Inhibitors (SGLT2i)

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease